ArticleJournal of veterinary internal medicine2026
Prognosis and associated risk factors after conservative management of dogs with liver tumors.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInformation is limited regarding prognosis for conservatively managed hepatic tumors in dogs. HYPOTHESIS/
objectivesReport prognosis and identify prognostic factors in dogs with conservatively managed hepatic tumors. ANIMALS: Client-owned dogs (n = 49) with hepatic tumors characterized by computed tomography (CT) without directed treatment that had died or were euthanized by the time of analysis.
methodsRetrospective, single institutional study utilizing the Schwarzman Animal Medical Center medical record system to identify all dogs from 2013 to 2023 that met the inclusion criteria. Data collected included signalment, presenting complaints, blood test results, diagnosis, tumor imaging characteristics, and date of death.
resultsMedian survival time from date of diagnosis was 313 days (range, 2-1308). Dogs with a presenting complaint of weight loss (P = .03) had a significantly shorter median survival time (128 days) than those without weight loss (341 days). Dogs presented with abdominal effusion (P = .03) had a significantly shorter median survival time (227 days) than dogs without effusion (331.5 days). Dogs with multiple hepatic masses (P = .004) had a significantly shorter median survival time (209.5 days) than dogs with a solitary mass (346 days). Higher aspartate aminotransferase (AST) activity and lower hematocrit (Hct) within 30 days of CT were associated with shorter median survival times (P = .02 and P = .01, respectively). Tumor volume/body weight ratio was not significantly related to survival time (P = .8). CONCLUSIONS AND CLINICAL IMPORTANCE: Poor prognostic factors for dogs with hepatic tumors include weight loss, abdominal effusion, multiple hepatic masses, increased AST activity, and low Hct.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.